ATRA · Atara Biotherapeutics, Inc.

Atara Biotherapeutics announced first quarter 2026 financial results reflecting substantial cost reductions from 2025 initiatives, driving net cash used in operations down to $3.1 million from $28.1 million year-over-year. Revenues dropped to $0.5 million from $98.1 million due to a one-time acceleration in the prior period tied to transferring tab-cel manufacturing to Pierre Fabre Laboratories. R&D expenses fell to $0.2 million from $27.4 million, and G&A to $3.6 million from $11.5 million, with non-cash stock-based compensation also declining significantly. This resulted in a net loss of $4.1 million or ($0.29) per share, contrasting sharply with Q1 2025 net income of $38.0 million or $3.50 diluted EPS. Balance sheet shows cash at $8.4 million as of March 31, 2026, nearly flat from year-end 2025. Management highlights that Q1 cash plus $4.8 million post-quarter ATM proceeds and efficiencies extend runway into mid-2027, with operating expenses set to decline further. Operationally, a productive FDA meeting paves way for tab-cel BLA resubmission by Pierre Fabre using updated ALLELE Phase 3 data, with regulatory update anticipated in Q3 2026. This progress on tab-cel for EBV+ PTLD underscores pipeline potential amid streamlined operations.